Skip to main content
NIH funding notice RFA-CA-24-021

Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)

Closed on March 6, 2024.

Posted
December 6, 2023
Close date
March 6, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,390,720 in first-year total cost, median $1,390,720.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 RTRB-F (O1)]1

Most frequent institutions

  1. STANFORD UNIVERSITY1
Competing awards under RFA-CA-24-021 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Next Generation GPC2-CARs for Medulloblastoma1UG3CA297747-01FELDMAN, STEVEN AMACKALL, CRYSTALSTANFORD UNIVERSITY, CA$1,390,720ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-24-021: Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) | ScienceDex | ConductScience